Bio-Thera Secures FDA Approval for Avzivi, a Biosimilar to Roche’s Avastin
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced that it has received market approval from the...
Mabwell Secures NMPA Approval for Phase III Study of ADC 9MW2821 in Urothelial Carcinoma
Mabwell (Shanghai) Bioscience Co., Ltd. (SHA: 688062) has announced that it has received approval from...
HutchMed’s Sovleplenib Set for Priority Review in China for Chronic Immune Thrombocytopenia
China’s Center for Drug Evaluation (CDE) has indicated that HutchMed (China) Ltd (NASDAQ: HCM; HKG:...
Trinomab’s TNM002 Antitetanus Monoclonal Antibody Filing Accepted for Review in China
China’s Center for Drug Evaluation (CDE) has accepted Trinomab Biotech Co., Ltd.’s market approval filing...
BMS Broadens Scope of IMID Collaboration, Aiming for Deeper Insights into Sjögren’s and Atopic Dermatitis
Bristol Myers Squibb (BMS; NYSE: BMY) has expanded its 2016 partnership with IMIDomics, broadening the...
Eli Lilly Seeks Approval for Pirtobrutinib in China for Relapsed Mantle Cell Lymphoma
Eli Lilly (NYSE: LLY) has submitted a marketing approval application for pirtobrutinib, an oral, non-covalent...
AbbVie to Acquire Cerevel Therapeutics for $8.7 Billion, Strengthening Neuroscience Portfolio
AbbVie (NYSE: ABBV) has announced its agreement to acquire Cerevel Therapeutics (NASDAQ: CERE) for approximately...
Shenzhen TargetRx’s TGRX-678 Set to Receive Breakthrough Therapy Designation for CML-AP
Shenzhen TargetRx, Inc., a China-based developer of small-molecule kinase inhibitors, is poised to receive breakthrough...
Quinovare Partners with AIM Vaccine to Enhance Vaccine Accessibility in China
Quinovare Medical Technology Co., Ltd., a China-based specialist in needle-free injectors, has announced a strategic...
Hisilicon Medical Technology Secures Nearly RMB 100 Million in Series A Funding
Guangdong Hisilicon Medical Technology Co., Ltd., a China-based firm, has successfully raised nearly RMB 100...
Changchun BCHT Secures NMPA Approval for Freeze-Dried Human Rabies Vaccine Trials
Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has...
Shanghai Pharmaceuticals Gains NMPA Approval for WST04 Clinical Trials in Oncology
Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading pharmaceutical distribution company in China, has...
Jiangsu Hengrui Seeks NMPA Approval for Camrelizumab-Famitinib Combo in Cervical Cancer
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), based in China, has announced that its market...
Boehringer Ingelheim Partners with Ten63 Therapeutics to Discover Novel Drug Molecules
Boehringer Ingelheim (BI), based in Germany, has announced a collaboration with U.S. drug discovery firm...
Antengene Secures NDA Approval for Xpovio in Macau for Advanced Multiple Myeloma
Antengene Corp., Ltd. (HKG: 6996), a biopharmaceutical company based in China, has announced that it...
Innovent Biologics Expands Partnership with Synaffix for New ADC Development
Innovent Biologics Inc. (HKG: 1801) has announced an expanded partnership with U.S.-based Synaffix B.V., a...
Taiwan Bio and TRACT Therapeutics Forge Partnership to Combat Organ Rejection
Taiwan Bio Therapeutics Co., Ltd. has entered into a strategic partnership with U.S.-based TRACT Therapeutics,...
Pfizer Allegedly Disbands Prevenar 13 Team in China Amid Industry Competition
Unconfirmed online reports suggest that Pfizer (NYSE: PFE) has dismissed its entire 400-person team for...
Novartis’ Fabhalta Wins FDA Nod as First-in-Class Treatment for Paroxysmal Nocturnal Hemoglobinuria
Swiss pharmaceutical giant Novartis (NYSE: NVS) has secured regulatory approval from the US Food and...
AbbVie Partners with BigHat Biosciences to Develop Next-Gen Antibodies for Oncology and Neuroscience
AbbVie (NYSE: ABBV) has enlisted the expertise of BigHat Biosciences, a US-based company specializing in...